Breaking Barriers to Diabetes Control with GLP-1 RA/Insulin Combination Agents: Opportunities for the Community Pharmacist

Breaking Barriers to Diabetes Control with GLP-1RA/Insulin Combination Agents: Opportunities for the Community Pharmacist

Provided by The University of Tennessee College of Pharmacy.
Supported by an educational grant from Sanofi US.

OVERVIEW

Emerging insulin combination therapies, including glucagon-like peptide 1 receptor agonists (GLP-1RAs)/insulin fixed-dose combinations (FDCs), have the capacity to address a number of unmet treatment needs that persist among patients with type 2 diabetes mellitus (T2DM). These novel agents offer improved A1c control with reduced potential for hypoglycemia and weight gain and less stringent injection requirements. Community pharmacists represent ideal clinicians to, not only, educate patients about their diabetes therapeutic regimens and inform evidence-based treatment decisions, but also to facilitate improvements in self-management, adherence, and appropriate utilization of GLP-1RA/insulin FDCs, among other T2DM treatments. As such, it is essential that pharmacists understand the clinical utility of these new therapies and are able to effectively implement practical strategies to educate patients on the injection principles of combination agents and on overall T2DM self-management.

GOAL

This archived webcast activity will provide the most up-to-date clinical evidence of the rationale, efficacy, and safety of fixed-dose GLP-1RA/insulin combinations as a treatment strategy for patients with T2DM. It will also provide community pharmacist-driven strategies to assess patient eligibility for these therapies, manage patients using these therapies, as well as provide appropriate and effective education about the injection devices and self-injection techniques.

TARGET AUDIENCE

This activity has been designed to meet the needs of community pharmacists, as well as other pharmacists who manage patients with T2DM. No prerequisites required.

LEARNING OBJECTIVES

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • COMPARE the safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of select injectable diabetes agents including basal insulin, GLP-RA, and fixed-dose combination GLP-1RA/insulin products.
  • IDENTIFY patients who may benefit from GLP-1RA/insulin combination.
  • DISCUSS differences between injection devices and self-injection protocols of available GLP-1RA/insulin combination agents.
  • DEVELOP strategies to educate patients on diabetes management and appropriate use of GLP-1RA/insulin delivery devices.

CONTINUING EDUCATION INFORMATION

acpeThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.5 contact hours of credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) studying the educational activity; 3) evaluating the activity; and, 4) completing the self-assessment instrument with a score of at least 70%. UAN: 0064-0000-18-201-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

The estimated time to complete this activity: 1.5 hours.

Release date

June 25, 2018

Expiration date

June 25, 2019

FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES

As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

STEERING COMMITTEE

James Wheeler, PharmD, BCPS
Assistant Professor Clinical Pharmacy and Translational Science
Director of Continuing Professional Development
College of Pharmacy
University of Tennessee Health Science Center
Nashville, Tennessee
Dr Wheeler reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Kira Brice Harris, PharmD, BCPS, CDE, CPP
Clinical Pharmacy Specialist
Novant Health Family Medicine Residency Clinic
Associate Professor
Wingate University School of Pharmacy
Wingate, North Carolina
Dr Harris reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

OFF-LABEL PRODUCT DISCUSSION

In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.

DISCLAIMER STATEMENT

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Grievance Policy

A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or coprovided by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

FEE INFORMATION

There is no fee for this educational activity.

ACTIVITY

Please complete the preassessment, listen to the following presentation, and complete the postassessment and evaluation to receive CPE credit for this activity. A statement of credit will be available online immediately following successful completion of the activity.

Preassessment

Introduction:
Overcoming Challenges in Diabetes Control Utilizing Conventional Agents
James Wheeler, PharmD, BCPS

Patient Case Introduction
James Wheeler, PharmD, BCPS

GLP1-RA/Insulin Fixed-Ratio Combinations: 
Whom Are They Indicated for? What Are the Benefits? What Are the Risks?

James Wheeler, PharmD, BCPS, and Kira Brice Harris, PharmD, BCPS, CDE, CPP

Reviewing Patient Cases: 
Focusing on Practical Management and Counseling Points

Kira Brice Harris, PharmD, BCPS, CDE, CPP

Considerations for Administration, Counseling/Educating, and Managing Adverse
Events of Fixed-Dose Combination GLP1-RA/Insulin

Kira Brice Harris, PharmD, BCPS, CDE, CPP

Practical Considerations: 
Advanced Scenarios that May Be Seen in Practice

James Wheeler, PharmD, BCPS, and Kira Brice Harris, PharmD, BCPS, CDE, CPP

Conclusions and Q & A
James Wheeler, PharmD, BCPS

Postassessment and Evaluation

What you are about to see is a previously recorded live meeting. Please note that only "home study" credit will be awarded for participating in this archived presentation. No "live" credits are available.

Postgraduate Healthcare Education, LLC (PHE) is the source of Power-Pak C.E.® continuing education for health care professionals. Our accredited programs assist in meeting the requirements of licensure. PHE provides continuing education for the broad spectrum of health care professionals. This site features a searchable database of accredited Power-Pak C.E.® courses on important topics for today's health care professionals.

PHE customizes Power-Pak C.E.® online for each visitor by creating a personal participant profile. Registered participants may update their contact information, take an exam, receive instant grading, view their exam history, and print certificates for successfully completed programs at any time. Monthly notifications will be sent to participants notifying you of new courses available on the site.